Kornimate/medical-research-clean huggingface dataset:
positive imagery therapy and the incidence of emergence reactions with the use of ketamine

Conditions: Procedural Sedation; Emergence Delirium

Summary: the purpose of this study is to determine if positive imagery therapy while using ketamine in procedural sedation reduces the number of emergence reactions and impacts pre and post-procedural anxiety.

this is a multi-center, randomized controlled trial looking at if positive imagery therapy while using ketamine during procedural sedation will reduce the number of emergence reactions and impacts pre and post procedural anxiety. after informed consent has been established and the subject is determined to meet eligibility criteria, participants will be randomized into 2 groups. the interventional group will undergo positive imagery therapy during sedation and the control will not. the duration of subject participation will be from the onset of sedation beginning until the patient is recovered.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * requires procedural sedation in the emergency department for whom ketamine is selected by the provider as the medication for procedural sedation exclusion criteria: * age below 18 years of age * any patient with a contraindication to the use of ketamine for the procedural sedation * any prisoners * pregnant females

Keywords: ketamine
a study assessing repatha® in combination with standard of care (soc) compared with soc on major cardiovascular events in chinese participants with atherosclerotic cardiovascular disease

Conditions: Major Cardiovascular Event; Established Atherosclerotic Cardiovascular Disease

Summary: the primary objective of the study is to evaluate real-world effectiveness of treatment with repatha® in combination with soc, compared with soc alone, on the risk for cardiovascular (cv) death, myocardial infarction (mi), stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in participants with established atherosclerotic cv disease (ascvd) treated with soc, according to local clinical practice.


Eligibility criteria:
inclusion criteria: * adult participants ≥ 18 years of age. * participants or participant's legally authorized representative has provided informed consent to participate in this study. * participants who meet one of the following: * prescribed repatha® in addition to an existing soc treatment according to local guidelines and approved label. or * already received soc treatment prior to enrollment. * participants with any of the following. * diagnosis of mi or stroke within 2 years before enrollment. * 2 mis or ≥ 2 strokes or (≥ 1 mi and ≥ 1 stroke) any time before enrollment. * diagnosis of (mi or stroke) and diabetes. * diagnosis of (mi or stroke) and documented multivessel disease (defined as \> 50% stenosis of ≥ 2 major coronary arteries on coronary angiography or coronary artery contrast enhanced computed tomography). * diagnosis of symptomatic peripheral arterial disease. * most recent fasting ldl-c ≥ 70 mg/dl (≥ 1.8 mmol/l) or nonhigh-density lipoprotein cholesterol (non-hdl-c) ≥ 100 mg/dl (≥ 2.6 mmol/l) within 6 months prior to enrollment. * most recent fasting triglycerides ≤ 400 mg/dl (≤ 4.5 mmol/l) within 6 months prior to enrollment. exclusion criteria: * stroke within past 1 month. * known hemorrhagic stroke at any time. * stroke due to thromboembolic event. * any prior use of repatha® or other proprotein convertase subtilisin/kexin type 9 inhibition treatments within past 6 months prior to enrollment. * participants currently enrolled in another study involving any investigational procedure, device or drug. * participants prescribed repatha® with a history of severe hypersensitivity or allergy to any subsidiary.

Keywords: cardiovascular death myocardial infarction stroke unstable angina coronary revascularization atherosclerotic cardiovascular disease repatha
evaluating a pharmacokinetic drug interaction between metformin hydrochloride and rosuvastatin calcium

Conditions: Diabetes Mellitus

Summary: we investigate the potential pharmacokinetic drug-drug interaction between metformin extended release and rosuvastatin in healthy male volunteers who receive metformin extended release alone, rosuvastatin alone, and both together in a 3 period repeatedly.


Eligibility criteria:
inclusion criteria: 1. healthy male volunteers, age 20 to 55 years. 2. the result of body mass index(bmi) is not less than 19 kg/m2 , no more than 27 kg/m2 3. subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing exclusion criteria: 1. presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system. 2. glomerular filtration rate is under 60ml/min which is calculated by serum creatinine value. 3. liver enzyme (ast, alt) level exceeds one and a half times more than maximum normal range. 4. systolic blood pressure \<90mmhg or diastolic blood pressure \< 60 mmhg, systolic blood pressure ≥ 140 mmhg or diastolic blood pressure ≥ 90 mmhg(sitting blood pressure) during the screening procedure.
a study of the pharmacokinetics and safety of varespladib in subjects with normal or impaired renal function

Conditions: Renal Impairment

Summary: the purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of varespladib methyl in mild or moderate renal impairment patients and healthy volunteers.


Eligibility criteria:
inclusion criteria: * males and non-pregnant, non-lactating females 18 years or older with a bmi of 18-40 kg/m2 inclusive. * regarding renal function, subjects will be classified as either normal or as suffering from mild,moderate or severe renal impairment. classification of renal impairment will be estimated by the mdrd and cockcroft-gault formulae exclusion criteria: * any disease, condition and/or chronic medications which might compromise the hematologic, cardiovascular, pulmonary renal, gastrointestinal, hepatic, or central nervous system; or other conditions that might interfere with the distribution, metabolism or excretion of study drug, or would place the subject at increased risk * evidence of significant respiratory, gastrointestinal or hepatic disease at screening * positive screen for hepatitis b surface antigen, or hiv * positive test in drugs of abuse screens or alcohol on admission to the clinic

Keywords: renal impairment phase 1 healthy volunteers
thrombolysis endovascular treatment of pulmonary embolism

Conditions: Pulmonary Embolism; Acute Pulmonary Embolism

Summary: to assess the efficacy and safety of endovascular thrombolysis of pulmonary embolism with right ventricular dysfunction with single-dose rtpa

the patients with right ventricular dysfunction who are diagnosed by ct pulmonary angiography will receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the in this study. the change of rv to lv diameter ratio,rate of death,rate of major bleeding,pulmonary embolism recurrence at 1month will be reviewed to assess the efficacy and safety.

Eligibility criteria:
inclusion criteria: * ct evidence of proximal pe * age ≥ 18 years * pulmonary embolism symptom duration ≤14 days * massive pe (syncope, systemic arterial hypotension, cardiogenic shock, or resuscitated cardiac arrest) or submassive pe (rv diameter-to-lv diameter ≥ 0.9 on contrast-enhanced chest ct) exclusion criteria: * age \<18 years * pe symptom duration \>14 days * stroke or transient ischemic attack (tia), head trauma, or other active intracranial or intraspinal disease within one year * recent (within one month) or active bleeding from a major organ * pregnancy * chronic pulmonary hypertension or severe chronic obstructive pulmonary disease * administration of thrombolytic agents within the previous 3 days * life expectancy \< 30 days * any other condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated * inability to follow protocol requirements

Keywords: acute pulmonary embolism
clinical study of light therapy to control myopia progression in children

Conditions: Myopia, Progressive

Summary: low-lever red light therapy (lllt) has been used to control myopia progression in china for a few years besides amblyopia therapy for a few decades. this study is to test the efficacy of pbm therapy to myopia children as well as to compare two types of pbm therapy to control myopia progression within one month.

lllt utilized the 650-nm red light to provide sufficient energy to stimulate the tissue without causing damage to the surrounding tissues. and several researchers reported the long-term efficacy of lllt in slowing the progression of myopia to date. these studies were reported various illumination and irradiance. this study is to test the efficacy of lllt comparing to the control group as well as to test whether two types of lighting design will be different to the efficacy and safety.

Eligibility criteria:
inclusion criteria: 1. grade 1 to grade 9 and age 6 to 16 years (including 6 and 16 years), sex is not limited; 2. equivalent sphere (ser): -0.50d \~ -6.00d (including-0.50 and-6.00d); 3. best corrected vision in one eye under glasses correction: 0.1 log mar; 4. no strabismus: no more than 15 prism constant dominance strabismus after far and near cover tests; 5. no myopia control measures within the previous 4 weeks: such as orthokeratology lens, gradient lens, double light lens, eye drops for myopia control (such as atropine), myopia defocus glasses, red light for myopia control, other specially designed myopia light treatment instruments or contact lenses for special design to control myopia (such as misight); exclusion criteria: 1. any ocular(including constant dominant strabismus with more than 15 prisms) and systemic diseases or abnormalities can significantly affect visual function or promote the progression of myopia; 2. other interventions for myopia control before 4 weeks before enrollment, for example, orthoplastic lens, gradient lens, dual-light lens, eye drops for myopia control (atropine), myopia defocus glasses, red light therapy devices for myopia control, other specially designed comprehensive treatment devices, myopia, amblyopia, or specially designed contact lenses (such as misight), etc. 3. subject participated in other clinical trials within 4 weeks before the enrollment; 4. the investigator for safety reasons or the interests of the patient, other circumstances in which the patient should not participate in this trial, if suffering from serious heart, liver and kidney disease. -
sonographic evaluation of uterine fibroids at different locations in patient with irregular menstrul cycle

Conditions: Menstrual Irregularity

Summary: uterine fibroids are a major cause of illness in women of a reproductive age. there are many factors involved in the growth and reduction of these common tumors. the most likely cause of fibroids is their effect on a woman's menstrual cycle. for accurate diagnosis numerous diagnostic markers on ultrasound are present which increases the efficacy of ultrasound to diagnose uterine fibroids.

to evaluate the different location of uterine fibroids in patient with disturbed menstrual cycle on ultrasound. the descriptive and cross-sectional study was conducted. a total of 97 patient data were collected. all the patients with uterine fibroids due to heavy bleeding, abdominal pain, pelvic pain, disturbance in menstrual cycle undergoing ultrasound were included.

Eligibility criteria:
inclusion criteria: * patient with pelvic pain * patient with abdominal pain * patient with heavy bleeding * patient with dysmenorrhea * polymenorrhea exclusion criteria: * patient with h/o cystectomy * patient with h/o cyst
the incidence and risk factors of postoperative delirium

Conditions: Delirium in Old Age

Summary: delirium is known to be one of the most common postoperative complications in elderly patients undergoing surgery. because postoperative delirium can affect the length of hospital stay and prognosis significantly, it is important to identify the risk factors for postoperative delirium in advance. however, there have been few reports concerning intraoperative modifiable risk factors, such as postoperative pain, for postoperative delirium.

in this observational study, we will review the electronic medical records of elderly patients underwent spine surgery and assess the incidence and risk factors for postoperative delirium.

Eligibility criteria:
inclusion criteria: * patients who underwent spine surgery between september 2016 and august 2018 at seoul national university hospital exclusion criteria: * patients who had no information on postoperative care and managements.

Keywords: postoperative delirium elderly spine surgery
assessment of duodenal epithelial integrity in celiac disease with mucosal impedance

Conditions: Celiac Disease

Summary: increased intestinal permeability can represent compromise of the epithelium's integrity and is thought to be the primary mechanism in patients who develop celiac disease (ced) and non-celiac gluten sensitivity when gluten peptides cross the barrier and trigger an immune response. in this study, the investigators propose to use a novel, minimally invasive technology to detect mucosal damage (i.e. barrier dysfunction) in the duodenal epithelium. the primary aim of this study is to identify if there is a difference in duodenal mucosal impedance between ced and control patients.


Eligibility criteria:
inclusion criteria: * scheduled for endoscopy as part of routine care with or without suspected celiac disease based upon at least 1 positive serologic marker of ced * consuming gluten at time of endoscopy exclusion criteria: * already on a gluten free diet or unwilling to undergo a gluten challenge * undergoing upper endoscopy for an urgent indication such as unstable gastrointestinal bleed or food impaction * patients with inflammatory bowel disease * patients on blood thinners other than aspirin at time of endoscopy * patient unable to give informed consent * patient less than 18 years old
interdisciplinary platform for rehabilitation research and innovative care of stroke patients

Conditions: Stroke

Summary: observational study of functional recovery of stroke patients after discharge from rehabilitation

cerebrovascular diseases, such as stroke, are among the greatest challenges in healthcare. this proves the importance of neuro-rehabilitative research. stroke research is often focused on the acute treatment phase as well as the inpatient rehabilitation. a remaining question is how do stroke patients clinically develop after being discharged from the hospital? how stable are the achieved rehabilitation effects and how much more clinical improvement is seen in the following time period, especially with regard to icf functionality? in this observational longitudinal study, the current practice of neurorehabilitation will be investigated and the influence of motor skills, cognition, care situation, depression, information and fatigue on functional recovery as well as participation, autonomy and quality of life will be evaluated. stroke patients will be examined at the end of rehabilitation, after three, six and 12 months. in addition, a group of chronic patients undergoes the same examinations and thereby represents a comparison group.

Eligibility criteria:
inclusion criteria: * ischemic or haemorrhagic stroke according to icd 10 i61-i69 * patients in or after completion of rehabilitation phases c and d according to bar criteria * age \>= 18 * sufficient knowledge of german * existing declaration of consent * deficit still existing (rankin score of at least 1 at inclusion) exclusion criteria: * need for care prior stroke * sab, craniocerebral trauma, tia as primary diagnosis * severe pre-existing psychiatric disease * participation in follow-up examination not possible

Keywords: functional recovery neurorehabilitation stroke
a comparative study of two dry needling interventions for plantar heel pain

Conditions: Plantar Fascitis; Myofacial Pain Syndromes; Trigger Point Pain, Myofascial

Summary: this is a clinical trial that will be done in the state of kuwait, at the physical rehabilitation medicine hospital. the participants will be recruited from all over kuwait, there is a clinical registry upon the ethical committee in kuwait assigned by the ministry of health.

physical therapy approaches continue evolving. during the last years, minimally invasive techniques such as percutaneous needle electrolysis (pne) was being developed, obtaining promising results for tendon pathology. pne technique is a minimally invasive treatment that consists of an application of a galvanic electrolytic current that causes a controlled local inflammatory process in the target tissue. this allows for phagocytosis and the subsequent regeneration of the affected tissue. nowadays, pne is being used in clinical practice to manage mtrp, but there are no studies supporting that they have an additional beneficial effect over dn. from a biological point of view, it seems reasonable to ascertain that a patient will obtain benefits thanks to the mechanical effects provided by the needle and that patients may benefit more if the electrolysis effect is added to the mechanical stimuli provided by the needle. therefore, the aim of this randomized controlled study is to compare the effectiveness of dn versus pne for the level of pain in patients suffering from php.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of php in accordance with the clinical guidelines linked to the international classification of function, disability, and health from the orthopedic section of the american physical therapy association * age greater than 21 years according to the kuwaiti law. * history of plantar heel pain for greater than one month. * walking 50 meters without any support * having mtps on initial physical examination on plantar and calf muscles * accepting to be treated by a male physiotherapist. * capacity to understand the study and the informed consent, as well as having signed the document. exclusion criteria: * - needle phobia * allergy from needles or hypersensitivity to metals * presence of coagulopathy or use of anticoagulants * presence of peripheral arterial vascular disease * pregnancy * dermatological disease with the dry needling area * the presence of a chronic medical condition that might preclude participation in the study such as malignancy, systemic inflammatory disorders (e.g. psoriatic arthritis, ankylosing spondylitis, septic arthritis), neurological diseases, polyneuropathy, mononeuropathy. * treatment of plantar heel pain with needling or acupuncture during last 4 weeks. * a history of injection therapy in the heel in the previous three months. * previous history of foot surgery or fracture.
technology enhanced nurse navigator trial (tenn trial)

Conditions: Medication Adherence

Summary: the purpose of the technology enhanced nurse navigator trial (tenn) trial is to find the best way to provide breast cancer patients with information through a computer connected to the internet. the study will determine if giving information during treatment may help patients cope better with their treatment. the hypothesis is that participants assigned to receive technology-enhanced nurse-directed navigation will be more likely to adhere to treatment regimens and have improved symptom management than women who have access to the education portal only.

treatment for breast cancer has been proven to decrease death from breast cancer. the key to the success of treatment is getting the right dose at the right time, but many women do not receive optimum treatment. treatment delays, missed appointments, and failure to take medication on a regular basis lead to poorer survival from breast cancer. in a study among low income women only 60% of women adhered to the treatment, that is, taking their medication at least 80% of the time. twenty percent of women, who were supposed to take 5 years of hormone treatment, had stopped their medication in the first year. similar problems occur with chemotherapy and radiation therapy. many barriers interfere with adherence to treatment, including poor symptom management, missed appointments, and cancelled appointments. nurse navigation can help manage and minimize symptoms, assist with appointment reminders, and answer questions to obtain optimum breast cancer treatment. the goal of the proposed study is to rigorously test the delivery of nurse-navigation through a web-based knowledge and communication portal (technology enhanced nurse-directed navigation (tenn) for its impact on treatment adherence and symptom management. the success of this program will be measured by improved treatment adherence, health outcome measures such as fatigue and symptom management, patient-reported quality of life, reduced distress, and patient satisfaction.

Eligibility criteria:
inclusion criteria: * enrolled in the bccdt program for the adjuvant treatment of breast cancer,currently on medical assistance,or with an income that does not exceed 300% of the federal poverty level, based on family size. * english-speaking * able to give informed consent * not enrolled in another case-management program * residing within the verizon 3g coverage area exclusion criteria: * non-english speaking * enrolled in a case management program. * unable to sign an informed consent

Keywords: treatment adherence fatigue symptom management
the frequency of thyroid diseases in women with breast cancer

Conditions: Breast Cancer; Thyroid Diseases

Summary: breast cancer and thyroid disorders are important health challenges commonly encountered in women. the relationship between both conditions still remains unknown. in this study, the frequency of thyroid diseases was investigated in breast cancer patients


Eligibility criteria:
inclusion criteria: * women, the age between 18-65 years who were diagnosed with breast cancer, but not underwent surgery, radiotherapy or chemothreapy were included into the study exclusion criteria: * those with pregnancy, known liver and renal failure, the history of any malignancy other than breast cancer, undergoing a surgical operation due to breast cancer, also those receiving chemotherapy/radiotherapy for the same reason or undergoing partial or complete thyroid surgery or a surgical operation within the past 6 months, and also the patients taking oral anti-diabetic medication, insulin, steroids, thiazide, anti-psychotics and immuno-suppressive medicines affecting the levels of blood glucose, insulin and ir, smokers and those consuming alcohol were excluded